Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan 17;4(1):100906.
doi: 10.1016/j.xcrm.2022.100906.

Is psilocybin an effective antidepressant and what is its Mechanism of action?

J John Mann  1
Affiliations
Comment

Is psilocybin an effective antidepressant and what is its Mechanism of action?

J John Mann. Cell Rep Med. .

Abstract

Goodwin et al.1 report a single 25 mg dose of psilocybin has an antidepressant effect short-term in medication-resistant depression. Unanswered questions include drug blood level as a guide to dose, psychedelic effects relationship to antidepressant benefit, and potential suicide risk of psilocybin.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.J.M. receives royalties for commercial use of the C-SSRS from the Research Foundation for Mental Hygiene.

Comment on

  • Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
    Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.

References

    1. Goodwin G.M., Aaronson S.T., Alvarez O., Arden P.C., Baker A., Bennett J.C., Bird C., Blom R.E., Brennan C., Brusch D., et al. Single-dose psilocybin for a treatment-resistant Episode of major depression. N. Engl. J. Med. 2022;387:1637–1648. doi: 10.1056/nejmoa2206443. - DOI - PubMed
    1. Carhart-Harris R., Giribaldi B., Watts R., Baker-Jones M., Murphy-Beiner A., Murphy R., Martell J., Blemings A., Erritzoe D., Nutt D.J. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 2021;384:1402–1411. doi: 10.1056/nejmoa2032994. - DOI - PubMed
    1. González-Maeso J., Weisstaub N.V., Zhou M., Chan P., Ivic L., Ang R., Lira A., Bradley-Moore M., Ge Y., Zhou Q., Sealfon S.C., Gingrich J.A. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–452. doi: 10.1016/j.neuron.2007.01.008. - DOI - PubMed
    1. Madsen M.K., Fisher P.M., Burmester D., Dyssegaard A., Stenbæk D.S., Kristiansen S., Johansen S.S., Lehel S., Linnet K., Svarer C., Erritzoe D., Ozenne B., Knudsen G.M. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328–1334. doi: 10.1038/s41386-019-0324-9. - DOI - PMC - PubMed
    1. Howland R.H. Sequenced treatment alternatives to relieve depression (STAR∗ D)–Part 2: study outcomes. J. Psychosoc. Nurs. Ment. Health Serv. 2008;46:21–24. doi: 10.3928/02793695-20081001-05. - DOI - PubMed

MeSH terms